Gsa Capital Partners LLP Atossa Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$0.63 - $0.98 $64,064 - $99,656	101,690 Added 29.27%	449,082 $395,000
Q3 2023 Nov 15, 2023	BUY	$0.74 - $1.35 $33,143 - $60,463	44,788 Added 14.8%	347,392 $257,000
Q2 2023 Aug 14, 2023	BUY	$0.6 - $1.28 $181,562 - $387,333	302,604 New	302,604 $381,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.14 $58,958 - $81,967	71,901 New	71,901 $60,000
Q2 2022 Aug 09, 2022	SELL	$0.85 - $1.28 $56,289 - $84,765	-66,223 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$1.11 - $1.74 $73,507 - $115,228	66,223 New	66,223 $83,000
Q2 2021 Aug 05, 2021	SELL	$1.52 - $8.62 $34,846 - $197,613	-22,925 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$0.92 - $4.33 $21,091 - $99,265	22,925 New	22,925 $48,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.